Profile data is unavailable for this security.
About the company
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.
- Revenue in USD (TTM)591.00k
- Net income in USD-204.50m
- Incorporated2019
- Employees234.00
- LocationPrime Medicine Inc60 First St.CAMBRIDGE 02141United StatesUSA
- Phone+1 (617) 465-0013
- Fax+1 (302) 655-5049
- Websitehttps://primemedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 808.06m | 300.00 | -- | 2.26 | -- | 4.22 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 834.89m | 180.00 | -- | 3.16 | -- | 6.70 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 839.11m | 24.00 | -- | 3.74 | -- | 83,911.29 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Humacyte Inc | 0.00 | -105.70m | 839.54m | 183.00 | -- | 32.10 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 846.95m | 110.00 | -- | 5.38 | -- | 107.96 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 853.42m | 234.00 | -- | 3.50 | -- | 1,444.03 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 856.51m | 1.80k | 14.03 | 1.71 | 11.49 | 0.9512 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| 89bio Inc | 0.00 | -165.03m | 862.83m | 70.00 | -- | 1.64 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| OPKO Health Inc | 799.60m | -252.43m | 871.24m | 3.93k | -- | 0.6955 | -- | 1.09 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Rapport Therapeutics Inc | 0.00 | -51.31m | 888.81m | 58.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | 5.52 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Ocular Therapeutix Inc | 59.84m | -115.27m | 890.61m | 267.00 | -- | 2.18 | -- | 14.88 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Immunome Inc | 12.68m | -232.03m | 894.74m | 55.00 | -- | 3.12 | -- | 70.55 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 900.23m | 284.00 | -- | 4.42 | -- | 11.13 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Silence Therapeutics plc | 33.49m | -44.31m | 900.54m | 115.00 | -- | 5.77 | -- | 26.89 | -0.3894 | -0.3894 | 0.2843 | 1.13 | 0.1829 | -- | 5.37 | 291,211.50 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Data as of Jun 14 2024. Currency figures normalised to Prime Medicine Inc's reporting currency: US Dollar USD
24.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 5.99m | 4.99% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.72m | 4.77% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 3.36m | 2.80% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 3.09m | 2.57% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.69m | 2.24% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.51m | 2.09% |
| Redmile Group LLCas of 31 Mar 2024 | 2.07m | 1.73% |
| Avidity Partners Management LPas of 31 Mar 2024 | 1.99m | 1.66% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 1.03m | 0.86% |
| Geode Capital Management LLCas of 31 Mar 2024 | 916.86k | 0.76% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
